quickk schreef:
Wat is je bron en waarom heb je die niet eerder hier geplaatst zodat trouwe forumgangers hadden kunnen profiteren. Nu is de koers al 10% gestegen. Klinkmisschien een b-tje onaardig maar zo is het niet bedoeld. Meet ter lering voor de volgende nieuwsfeiten. Bedankt voor je bericht en laten we wel wezen wat is die 10%-stijging van vandaag als je binnekort weer de 8 euro op de borden ziet staan
[quote=ohoh]
Eindelijk weer een koersstijging en terecht ook want er is nieuws :
Amsterdam Molecular Therapeutics (Euronext: AMT) a world leader in gene therapy, today reports new data showing that it’s lead product Glybera results in break-down of chylomicrons in lipoprotein lipase deficient (LPLD) patients. The data will be presented on June 5 at the Second International Symposium on Chylomicrons in Disease, Sint Franciscus Gasthuis, Rotterdam, The Netherlands.
?Glybera is a gene therapy product that induces functional lipoprotein activity. New data from an ongoing Canadian clinical study indicate that a single administration of Glybera in LPLD patients results in a remarkable improvement in the ability to break down the chylomicrons that transport dietary fat (triglycerides).
Lipoprotein-lipase-deficient (LPLD) patients are incapable of clearing chylomicrons which are responsible for causing significant morbidity and mortality.
“The long-term improvement in chylomicron handling following Glybera administration is very impressive”, said Dr. André Carpentier, co-investigator from the University of Sherbrooke, Quebec, Canada, who designed and analyzed the chylomicron sub-study.
“These data are important, because the major complications observed in LPLD patients, including pancreatitis, are a consequence of chylomicron overload. They also constitute evidence for a long term clinically relevant lipoprotein lipase activity induced by Glybera” noted the principal investigator, Prof. Daniel Gaudet, from the University of Montreal, and ECOGENE-21 clinical study center, Chicoutimi, Quebec, Canada.
These new data provide a basis for explaining the mechanism of action of Glybera in LPLD patients, and in general for continued pharmacologic activity after one time gene therapy.
[/quote]